IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature

Experimental and Molecular Pathology

Volumn 91, Issue 1, 2011, Pages 385-393

  Jha, Prerana ^a   Suri, Vaishali ^a   Sharma, Vikas ^a   Singh, Geetika ^a   Sharma, Mehar Chand ^a   Pathak, Pankaj ^a   Chosdol, Kunzang ^a   Jha, Pankaj ^b   Suri, Ashish ^a   Mahapatra, Ashok Kumar ^a   Kale, Shashank Sharad ^a   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Diffuse astrocytoma; GBM; Gliomas; IDH1; Oligodendrogliomas

Indexed keywords

ARGININE; HISTIDINE;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTE; CANCER GRADING; CLINICAL PRACTICE; CODON; CONTROLLED STUDY; EGFR GENE; GENE; GENE DELETION; GENE FREQUENCY; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC MARKER; GENETIC SCREENING; GLIOMA; HUMAN; HUMAN TISSUE; INDIA; ISOCITRATE DEGYDROGENASE 1 GENE; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; OLIGODENDROGLIOMA; ONCOGENE; PATIENT ASSESSMENT; PHENOTYPE; PROGNOSIS; PTEN GENE; TERTIARY HEALTH CARE; TP53 GENE;

ADOLESCENT; ADULT; AGE FACTORS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GLIOMA; HOSPITALS, TEACHING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; ISOCITRATE DEHYDROGENASE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79955950884     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.04.017     Document Type: Article

References (31)

1. Balss J., et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116:597-602.
2. Bleeker F.E., et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 2009, 30:7-11.
3. Capper D., et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010, 20:245-254.
4. Dang L., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
5. Dubbink H.J., et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009, 73:1792-1795.
6. Felsberg J. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010, 119:501-507.
7. Gravendeel L.A., et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum. Mutat. 2010, 31:E1186-E1199.
8. Hartmann C. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009, 118:469-474.
9. Horbinski C., et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J. Neuropathol. Exp. Neurol. 2009, 68:1319-1325.
10. Horbinski C., et al. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J. Mol. Diagn. 2010, 12:487-492.
11. Ichimura K. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009, 11:341-347.
12. Jha P., et al. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genet. Cytogenet. 2010, 198:126-134.
13. Kang M.R., et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 2009, 125:353-355.
14. Kleihues P., et al. WHO grading of tumours of the central nervous system. WHO classification of tumours of the central nervous system 2007, 10-11. IARC, Lyon. 4th edn. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee (Eds.).
15. Loenarz C., et al. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat. Chem. Biol. 2008, 4:152-156.
16. Mardis E.R., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361:1058-1066.
17. Meyer J., et al. PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol. 2010, 20:298-300.
18. Nobusawa S. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 2009, 15:6002-6007.
19. Ohgaki H., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64:6892-6899.
20. Ohgaki H., et al. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005, 64:479-489.
21. Parsons D.W., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
22. Petitjean A., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
23. Sanson M., et al. Isocitrate dehydrogenase1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 2009, 27:4150-4154.
24. Sonoda Y., et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009, 100:1996-1998.
25. van den Bent M.J., et al. IDH1 and IDH2 mutations are prognostic but not predictive foroutcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 2010, 16:1597-1604.
26. Ward P.S., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
27. Watanabe K., et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996, 6:217-223.
28. Watanabe T., et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009, 174:1149-1153.
29. Weller M., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 2009, 27:5743-5750.
30. Yan H., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
31. Zhao S., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.